Literature DB >> 27629715

Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.

Mathew A Sherman1, Michael LaCroix1, Fatou Amar1, Megan E Larson1, Colleen Forster2, Adriano Aguzzi3, David A Bennett4, Martin Ramsden2, Sylvain E Lesné5.   

Abstract

UNLABELLED: Despite the demonstration that amyloid-β (Aβ) can trigger increased tau phosphorylation and neurofibrillary tangle (NFT) formation in vivo, the molecular link associating Aβ and tau pathologies remains ill defined. Here, we observed that exposure of cultured primary neurons to Aβ trimers isolated from brain tissue of subjects with Alzheimer's disease led to a specific conformational change of tau detected by the antibody Alz50. A similar association was supported by postmortem human brain analyses. To study the role of Aβ trimers in vivo, we created a novel bigenic Tg-Aβ+Tau mouse line by crossing Tg2576 (Tg-Aβ) and rTg4510 (Tg-Tau) mice. Before neurodegeneration and amyloidosis, apparent Aβ trimers were increased by ∼2-fold in 3-month-old Tg-Aβ and Tg-Aβ+Tau mice compared with younger mice, whereas soluble monomeric Aβ levels were unchanged. Under these conditions, the expression of soluble Alz50-tau conformers rose by ∼2.2-fold in the forebrains of Tg-Aβ+Tau mice compared with nontransgenic littermates. In parallel, APP accumulated intracellularly, suggestive of a putative dysfunction of anterograde axonal transport. We found that the protein abundance of the kinesin-1 light chain (KLC1) was reduced selectively in vivo and in vitro when soluble Aβ trimers/Alz50-tau were present. Importantly, the reduction in KLC1 was prevented by the intraneuronal delivery of Alz50 antibodies. Collectively, our findings reveal that specific soluble conformers of Aβ and tau cooperatively disrupt axonal transport independently from plaques and tangles. Finally, these results suggest that not all endogenous Aβ oligomers trigger the same deleterious changes and that the role of each assembly should be considered separately. SIGNIFICANCE STATEMENT: The mechanistic link between amyloid-β (Aβ) and tau, the two major proteins composing the neuropathological lesions detected in brain tissue of Alzheimer's disease subjects, remains unclear. Here, we report that the trimeric Aβ species induce a pathological modification of tau in cultured neurons and in bigenic mice expressing Aβ and human tau. This linkage was also observed in postmortem brain tissue from subjects with mild cognitive impairment, when Aβ trimers are abundant. Further, this modification of tau was associated with the intracellular accumulation of the precursor protein of Aβ, APP, as a result of the selective decrease in kinesin light chain 1 expression. Our findings suggest that Aβ trimers might cause axonal transport deficits in AD.
Copyright © 2016 the authors 0270-6474/16/369647-12$15.00/0.

Entities:  

Keywords:  Alzheimer's disease; amyloid-beta; axonal transport; brain; oligomer; tau

Mesh:

Substances:

Year:  2016        PMID: 27629715      PMCID: PMC5039246          DOI: 10.1523/JNEUROSCI.1899-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  47 in total

1.  Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Authors:  Martin Ramsden; Linda Kotilinek; Colleen Forster; Jennifer Paulson; Eileen McGowan; Karen SantaCruz; Aaron Guimaraes; Mei Yue; Jada Lewis; George Carlson; Michael Hutton; Karen H Ashe
Journal:  J Neurosci       Date:  2005-11-16       Impact factor: 6.167

2.  The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology.

Authors:  G Carmel; E M Mager; L I Binder; J Kuret
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

3.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

4.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

5.  Levels of kinesin light chain and dynein intermediate chain are reduced in the frontal cortex in Alzheimer's disease: implications for axoplasmic transport.

Authors:  Marina Morel; Céline Héraud; Charles Nicaise; Valérie Suain; Jean-Pierre Brion
Journal:  Acta Neuropathol       Date:  2011-11-18       Impact factor: 17.088

6.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

7.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

8.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.

Authors:  H Büeler; M Fischer; Y Lang; H Bluethmann; H P Lipp; S J DeArmond; S B Prusiner; M Aguet; C Weissmann
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

Review 9.  Breaking the Code of Amyloid-β Oligomers.

Authors:  Sylvain E Lesné
Journal:  Int J Cell Biol       Date:  2013-08-31

10.  Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Authors:  Sylvain E Lesné; Mathew A Sherman; Marianne Grant; Michael Kuskowski; Julie A Schneider; David A Bennett; Karen H Ashe
Journal:  Brain       Date:  2013-04-09       Impact factor: 13.501

View more
  23 in total

1.  Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction.

Authors:  Peter J Teravskis; Breeta R Oxnard; Eric C Miller; Lisa Kemper; Karen H Ashe; Dezhi Liao
Journal:  J Physiol       Date:  2019-07-07       Impact factor: 5.182

2.  Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.

Authors:  Jangampalli Adi Pradeepkiran; Manne Munikumar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-12-27       Impact factor: 5.121

3.  Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment.

Authors:  William L Neumann; Karin E Sandoval; Shirin Mobayen; Mahsa Minaeian; Stephen G Kukielski; Khush N Srabony; Rafael Frare; Olivia Slater; Susan A Farr; Michael L Niehoff; Audrey Hospital; Maria Kontoyianni; A Michael Crider; Ken A Witt
Journal:  RSC Med Chem       Date:  2021-05-26

Review 4.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

Review 5.  Religious Orders Study and Rush Memory and Aging Project.

Authors:  David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons.

Authors:  Shahzad S Khan; Michael LaCroix; Gabriel Boyle; Mathew A Sherman; Jennifer L Brown; Fatou Amar; Jacqeline Aldaco; Michael K Lee; George S Bloom; Sylvain E Lesné
Journal:  Acta Neuropathol       Date:  2018-07-11       Impact factor: 17.088

7.  The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation.

Authors:  Fatou Amar; Mathew A Sherman; Travis Rush; Megan Larson; Gabriel Boyle; Liu Chang; Jürgen Götz; Alain Buisson; Sylvain E Lesné
Journal:  Sci Signal       Date:  2017-05-09       Impact factor: 8.192

8.  Stabilization, Assembly, and Toxicity of Trimers Derived from Aβ.

Authors:  Adam G Kreutzer; Stan Yoo; Ryan K Spencer; James S Nowick
Journal:  J Am Chem Soc       Date:  2017-01-10       Impact factor: 15.419

Review 9.  Practical considerations for choosing a mouse model of Alzheimer's disease.

Authors:  Joanna L Jankowsky; Hui Zheng
Journal:  Mol Neurodegener       Date:  2017-12-22       Impact factor: 14.195

10.  Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.

Authors:  Hugo Geerts; Athan Spiros; Patrick Roberts
Journal:  Alzheimers Res Ther       Date:  2018-02-02       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.